Patent: 10,233,245
✉ Email this page to a colleague
Summary for Patent: 10,233,245
| Title: | Methods of treating inflammatory and autoimmune diseases with natalizumab |
| Abstract: | Natalizumab is a safe and efficacious treatment for inflammatory and autoimmune diseases, such as multiple sclerosis, Crohn\'s Disease, and rheumatoid arthritis. Rare occurrences of progressive multifocal leucoencephalopathy during treatment suggest the possibility that it may be related to natalizumab treatment. Monitoring for JCV and informing caregivers and patients about the manifestations of progressive multifocal leucoencephalopathy can improve the safety of natalizumab therapy. |
| Inventor(s): | Lieberburg; Ivan (Berkeley, CA) |
| Assignee: | BIOGEN MA INC. (Cambridge, MA) |
| Application Number: | 15/596,468 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,233,245
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Biogen Inc. | TYSABRI | natalizumab | Injection | 125104 | November 23, 2004 | ⤷ Start Trial | 2037-05-16 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
